ERBB2 and breast carcinoma: IMpassion050 evaluated the effectiveness and safety of atezolizumab combined with trastuzumab, pertuzumab, and preoperative neoadjuvant chemotherapy in early stage high‐risk HER2‐positive breast cancer patients.